268P - The cardiac protective effects of dexrazoxane on animal model of cardiotoxicity induced by combinatorial treatment of anthracycline and trastuzumab

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anticancer Agents
Complications/Toxicities of Treatment
Cancer Biology
Basic Scientific Principles
Biological Therapy
Presenter Jin Zhang
Citation Annals of Oncology (2014) 25 (suppl_4): iv85-iv109. 10.1093/annonc/mdu327
Authors J. Zhang, S. Zhang, T. Meng, X. Zhang, X. Hao, Y. Liu, M. Zhang, J. Liu, C. Li
  • The 3rd Department Of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, 300060 - Tianjin/CN



Cardiotoxicity is a well-recognized side effect induced by chemotherapeutic drugs such as anthracycline and trastuzumab through different mechanisms. Currently, accumulating evidence supports that dexrazoxane can minimize the risk of cardiotoxicity.


In this study, we investigated whether dexrzoxane could reduce cardiotoxicity in the treatment of anthracycline combined with trastuzumab. We randomly divided twenty-five experimental F344 rats into control group, chemotherapeutics and trastuzumab (DOX/Doc/Her) group and three chemotherapeutics, trastuzumab and dexrazoxane (DOX/Doc/Her/DZR) subgroups. General conditions, cardiac function, serum cardiac markers and cardiomyocyte apoptosis of the rats were evaluated.


We observed that the Left Ventricular Ejection Fraction was significantly higher in all DOX/Doc/Her/DZR subgroups than that in DOX/Doc/Her group (P < 0.01). The serum levels of MDA and cTnI between DOX/Doc/Her group and DOX/Doc/Her/DZR subgroups were significantly different. Additionally, cardiomyocyte apoptosis in DOX/Doc/Her/DZR subgroups was significantly less severe than that in DOX/Doc/Her group (P < 0.05).


Taken together, our results suggest that dexrazoxane can effectively reduce the cardiotoxicity induced by the combinatorial treatment of Trastuzumab and anthracycline.


All authors have declared no conflicts of interest.